
Generic Acomplia is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe,Generic Acomplia is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.
In the UK, it has been available since the end of July 2006. As of 2008, the drug was available in 56 countries. Generic Acomplia may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of Generic Acomplia in smoking-cessation therapy.
Copyright © 2004-2010 XLPharmacy.com - ALL Rights Reserved. Content, including graphics, photos etc. is property of XLPharmacy.com